INTRANASAL INHALATIONS OF BIOACTIVE FACTORS PRODUCED BY M2 MACROPHAGES IN THE TREATMENT OF PATIENTS WITH ORGANIC BRAIN SYNDROME

The aim of present study was to evaluate safety and clinical efficacy of inhalatory immunotherapy based on intranasal delivery of bioactive factors produced by M2 macrophages applied for treatment of patients with organic brain syndrome (OBS).

Materials and methods. The study under the NCT02957123 protocol (www.ClinicalTrails.gov) included thirty patients with OBS of various genesis (10 men and 20 women aged 18 to 81; Me, 62.5 years). Neurological assessment and the levels of 32 cytokines in the blood serum of patients were evaluated before and 2-3 days after completion of inhalation immunotherapy.

Intranasal inhalations of cell-free culture medium of M2 macrophages (2 mL, once a day for 28-30 days) were safe and well tolerated. None of 30 treated patients had severe adverse events and serious treatmentrelated side reactions. One month after starting the inhalations, a positive dynamics in neurological status was noted in all the patients. A marked clinical response was documented in twenty out of thirty patients (67%), which manifested as improvement, according to all scales and questionnaires. The neurological improvement was not reversed over 6 months of follow-up period. In other ten patients (33%), a moderate clinical response was shown as improvement of individual scores. The positive changes were as follows: 1) a 43% decrease in anxiety and depression scores (according to HADS scale, pU = 0.0008); 2) an increase of total motor activity (stability and gait) by 25%, pU = 0.0001); 3) correction of cognitive functions (MoCa test, pU = 0.007); 4) reduced number and intensity of the disease symptoms by 52% (pU = 0.0001). This marked clinical response to immunotherapy is shown to be associated with correction/normalization of serum hepatocyte growth factor (HGF) level.

Conclusion. Inhalation immunotherapy based on intranasal delivery of bioactive factors produced by M2 macrophages can improve neurological and functional recovery in patients with organic brain syndrome. 

1. Alcalá-Barraza S.R., Lee M.S., Hanson L.R., McDonald A.A., Frey W.H., McLoon L.K. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO and NT-4 to the CNS. J. Drug Target., 2010, Vol. 18, no. 3, pp. 179-190.

2. Baum E., Pawlaczyk K., Mackowiak B., Sosinska P., Matecka M., Kolodziejczak B., Musielak M., Breborowicz A. Levels of hepatocyte growth factor in serum correlate with quality of life in hemodialysis patients. Int. J. Clin. Exp. Pathol., 2015, Vol. 8, no. 10, pp. 13477-13482.

3. Benedict C., Kern W., Schultes B., Born J., Hallschmid M. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J. Clin. Endocrinol. Metab., 2008, Vol. 93, no. 4, pp. 1339-1344.

4. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F., Aaronson S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science, 1991, Vol. 251, no. 4995, pp. 802-804.

5. Chernykh E.R., Shevela E.Ya., Sakhno L.V., Tikhonova M.A., Petrovsky Ya.L., Ostanin A.A. The generation and properties of human M2-like macrophages: potential candidates for CNS repair? Cell Ther. Transplant., 2010, Vol. 2, no. 6, e.000080.01. doi: 10.3205/ctt-2010-en-000080.01.

6. Chernykh E.R., Kafanova M.Yu., Shevela E.Y., Adonina E.I., Sakhno L.V., Tikhonova M.A., Ostanin A.A. Autologous M2-like macrophage applications in children with cerebral palsy. Cell Ther Transplant., 2011, Vol. 3, no. 11, e.000092.01. doi: 10.3205/ctt-2011-en-000092.01.

7. Chernykh E.R., Kafanova M.Y., Shevela E.Y., Sirota S.I., Adonina E.A., Ostanin A.A., Kozlov V.A. Clinical experience with autologous M2-macrophages in children with severe cerebral palsy. Cell Transplant., 2014, Vol. 23, Suppl. 1, S97-104.

8. Chernykh E.R., Shevela E.Y., Starostina N.M., Morozov S.A., Davydova M.N., Menyaeva E.V., Ostanin A.A. Safety and therapeutic potential of M2-macrophages in stroke treatment. Cell Transplant., 2016, Vol. 25, no. 8, pp. 1461-1471.

9. Chopp M., Li Y. Stimulation of plasticity and functional recovery after stroke – cell-based and pharmacological therapy. European Neurological Review, 2011, Vol. 6, no. 2, pp. 97-100.

10. Crigler L., Robey R.C., Asawachaicharn A., Gaupp D., Phinney D.G. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp. Neurol., 2006, Vol. 198, no. 1, pp. 54-64.

11. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci., 2010, Vol. 99, no. 4, pp. 1654-1673.

12. Donnelly D.J., Popovich P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp. Neurol., 2008, Vol. 209, no. 2, pp. 378-388.

13. Drago D., Cossetti C., Iraci N., Gaude E., Musco G., Bachi A., Pluchino S. The stem cell secretome and its role in brain repair. Biochimie, 2013, Vol. 95, no. 12, pp. 2271-2285.

14. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol., 2005, Vol. 5, no. 12, pp. 953-964.

15. Gutierrez-Fernandez M., Fuentes B., Rodriguez-Frutos B., Ramos-Cejudo J., Vallejo-Cremades M.T., DiezTejedor E. Trophic factors and cell therapy to stimulate brain repair after ischaemic stroke. J. Cell Mol. Med., 2012, Vol. 16, no. 10, pp. 2280-2290.

16. Hallschmid M., Benedict C., Schultes B., Born J., Kern W. Obese men respond to cognitive but not to catabolis brain insulin signaling. Int. J. Obes. (Lond)., 2008, Vol. 32, no. 2, pp. 275-282.

17. Hamanoue M., Takemoto N., Matsumoto K., Nakamura T., Nakajima K., Kohsaka S. Neurotrophic effect of hepatocyte growth factor on central nervous system neurons in vitro. J. Neurosci. Res., 1996, Vol. 43, no. 5, pp. 554-564.

18. Hohlfeld R., Kerschensteiner M., Meinl E. Dual role of inflammation in CNS disease. Neurology, 2007, Vol. 68, no. 22, Suppl. 3, S58-S63.

19. Kerschensteiner M., Gallmeier E., Behrens L., Leal V.V., Misgeld T., Klinkert W.E., Kolbeck R., Hoppe E., Oropeza-Wekerle R.L., Bartke I., Stadelmann C., Lassmann H., Wekerle H., Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation. J. Exp. Med., 1999, Vol. 189, no. 5, pp. 865-870.

20. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry, 2000, Vol. 157, no. 5, pp. 683-694.

21. Lu D., Mahmood A., Qu C. Goussev A., Schallert T., Chopp M. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J. Neurotrauma, 2005, Vol. 22, no. 9, pp. 1011-1017.

22. Miyazawa T., Matsumoto K., Ohmichi H., Katoh H., Yamashima T., Nakamura T. Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J. Cereb. Blood Flow Metab., 1998, Vol. 18, no. 4, pp. 345-348.

23. Nakamura T., Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc. Jpn Acad., Ser. B Phys. Biol. Sci., 2010, Vol. 86, no. 6, pp. 588-610.

24. Sakhno L.V., Shevela E.Ya., Tikhonova M.A., Ostanin A.A., Chernykh E.R. The phenotypic and functional features of human M2 macrophages generated under low serum conditions. Scand. J. Immunol., 2016, Vol. 83, no. 2, pp. 151-159.

25. Shimamura M., Sato N., Waguri S., Uchiyama Y., Hayashi T., Iida H., Nakamura T., Ogihara T., Kaneda Y., Morishita R. Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction. Hypertension, 2006, Vol. 47, pp. 742-751.

26. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of IGF-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience, 2004, Vol. 127, no. 2, pp. 481-496.

27. Thorne R.G., Hanson L.R., Ross T.M., Tung D., Frey W.H. Delivery of interferon-β to the monkey nervous system following intranasal administration. Neuroscience, 2008, Vol. 152, no. 3, pp. 785-797.

28. Wright J.W., Harding J.W. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. J. Alzheimer’s Dis., 2015, Vol. 45, no. 4, pp. 985-1000.

29. Wright J.W., Kawas L.H., Harding J.W. The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog. Neurobiol., 2015, Vol. 125, pp. 26-46.

30. Yang X.T., Bi Y.Y., Feng D.F. From the vascular microenvironment to neurogenesis. Brain Res. Bull., 2011, Vol. 84, no. 1, pp. 1-7.

31. Yin Y., Cui Q., Li Y., Irwin N., Fischer D., Harvey A.R., Benowitz L.I. Macrophage-derived factors stimulate optic nerve regeneration. J. Neurosci., 2003, Vol. 23, no. 6, pp. 2284-2293.

32. Zhang Z.G., Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol., 2009, Vol. 8, no. 5, pp. 491-500.

33. Zhu J., Jiang Y., Xu G., Liu X. Intranasal administration: a potential solution for cross-BBB delivering neurotrophic factors. Histol. Histopathol., 2012, Vol. 27, no. 5, pp. 537-548.